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Aims: Management of patients with inherited cardiac ion channelopathy is hindered by 
variability in disease severity and sudden cardiac death (SCD) risk. We here investigated the 
modulatory role of hypertrophy on arrhythmia and SCD risk in sodium channelopathy. 
Methods and Results: Follow-up data was collected from 164 individuals positive for the 
SCN5A-1795insD founder mutation and 247 mutation-negative relatives. A total of 38 (obligate) 
mutation-positive patients died suddenly or suffered life-threatening ventricular arrhythmia. Of 
these, 18 were aged >40 years, a high proportion of which had a clinical diagnosis of 
hypertension and/or cardiac hypertrophy. While pacemaker implantation was highly protective in 
preventing bradycardia-related SCD in young mutation-positive patients, 7 of them  aged >40 
experienced life-threatening arrhythmic events despite pacemaker treatment. Of these, 6 had a 
diagnosis of hypertension/hypertrophy, pointing to a modulatory role of this co-morbidity. 
Induction of hypertrophy in adult mice carrying the homologous mutation (Scn5a
1798insD/+
) 
caused SCD and excessive conduction disturbances, confirming a modulatory effect of 
hypertrophy in the setting of the mutation. The deleterious effects of the interaction between 
hypertrophy and the mutation were prevented by genetically impairing the pro-hypertrophic 
response and by pharmacological inhibition of the enhanced late sodium current associated with 
the mutation.  
Conclusion: This study provides the first evidence for a modulatory effect of co-existing cardiac 
hypertrophy on arrhythmia risk and treatment efficacy in inherited sodium channelopathy. Our 
findings emphasize the need for continued assessment and rigorous treatment of this co-
















SCN5A mutations present with a broad spectrum of clinical phenotypes, including sudden 
cardiac death (SCD). Disease penetrance and severity varies between individuals carrying the 
same SCN5A mutation, and common co-morbidities may modulate arrhythmia and SCD risk 
with potential implications for anti-arrhythmic treatment efficacy. This study conducted in 
patients and mice, provides strong evidence for a modulatory role of hypertension/hypertrophy in 
modulating arrhythmic risk of the SCN5A-1795insD mutation. Our findings support the concept 
that SCN5A mutation-positive patients should be carefully monitored for the development of 
cardiac hypertension and hypertrophy during follow up, and that their clinical management 








Abbreviations list  
 
Scn5a/SCN5A  gene encoding the alpha subunit of the cardiac sodium channel 
WT   wild type for the Scn5a gene 
MUT   mutant for the Scn5a gene (Scn5a
1798insD/+
) 
TAC   transverse aortic constriction 
ECG   electrocardiogram 
PM   pacemaker 
ICD   implantable cardioverter defibrillator 
SCD   sudden cardiac death 
INa,L   late component of the sodium current 









The genetic basis of the Mendelian cardiac rhythm disorders associated with sudden cardiac 
death (SCD) has been brought into focus over the last 20 years with the discovery of a large 
spectrum of causal mutations in genes encoding components of cardiac ion channels.
1
 Although 
this enabled genetic testing and consequently improvements in clinical care, patient management 
is still hindered by the reduced penetrance and substantial variability in disease severity and SCD 
risk among mutation-positive individuals.
1
 Although co-morbidities are expected to modulate 
disease severity, these remain unexplored. Identification of disease modifiers in these disorders is 
however hindered by the substantial genetic heterogeneity across patients, as different mutations 
may be associated with different effects and thus also contribute to inter-individual variability.
2
 
Studies in large families that harbour founder mutations (where all affected individuals carry the 
same familial mutation) circumvent this limitation and therefore offer opportunities for the 
identification of modulatory factors.  
We have previously described a large Dutch family harboring a founder mutation, 
p.Tyr1795_Glu1796insAsp (previously called ‘SCN5A-1795insD’), in the SCN5A gene which 
encodes the major sodium channel isoform in heart (NaV1.5).
3,4
 This mutation displays multiple 
biophysical defects and causes ‘overlap’ sodium channelopathy with features of long QT 
syndrome, Brugada syndrome, and conduction disease.
5,6
 While variability in disease severity 
among mutation-positive individuals in this family is long recognized,
3
 predictors of arrhythmia 
and SCD risk have remained elusive. By combining clinical observations in the family with 
experimental studies in Scn5a
1798insD/+
 mice carrying the mouse homolog of the mutation, we 






and expression. In particular, the co-occurrence of cardiac hypertrophy was found to exacerbate 
cardiac conduction slowing and arrhythmia risk in the setting of the mutation, and was associated 
with a decreased efficacy of pacemaker treatment in preventing SCD. Our findings furthermore 











Details on study approval, SCN5A-1795insD mutation study population, clinical data collection, 







aortic constriction (TAC) and chow experiments, electrophysiological assessments in 
Langendorff-perfused hearts, quantitative PCR assay and analysis and whole-mount in situ 
hybridization, and statistical analysis are provided in the Supplementary Methods. Data are 










Hypertension and hypertrophy in older SCN5A-1795insD mutation-positive patients who died 
suddenly  
Through an extensive genealogical search, we reconstructed the pedigree of the family with the 
SCN5A-1795insD mutation back to the 18
th
 century, linking 164 mutation-positive individuals  
and 247 mutation-negative relatives (Figure 1A). Mutation-positive patients displayed (atrio-
)ventricular conduction slowing, sinus node dysfunction, excessive ventricular repolarization 
abnormalities at slow heart rates, and SCD occurring predominantly at night.
3,4
 A total of 38 
individuals died suddenly or suffered life-threatening ventricular arrhythmia (13 males, 25 
females; average age at event 38±18 years, range 13-76) (Figure 1A,B). Twenty-five of these 
individuals were confirmed or obligate mutation-positive; genetic testing was not possible in the 
rest as these were deceased individuals from past generations, the majority of which died more 
than 50 years ago. Eighteen individuals who suffered SCD or a life-threatening arrhythmia were 
older than 40 years at the time of the event (4 males, 14 females, average age 54±9 years, range 
41-76) (Figure 1A,B). Recent clinical information was available for 10 of these (all confirmed 
mutation-positive); 9 of them had a clinical diagnosis of hypertension and/or evidence for the 
presence of left ventricular hypertrophy (including increased heart weight) on MRI, 
echocardiography or post-mortem examination (Table 1), suggesting a modulatory effect of 
cardiac hypertrophy on arrhythmia risk. Post-mortem analysis furthermore indicated the 
additional presence of slight interstitial fibrosis (potentially hypertension-related) in 3 out of 4 
patients (Table 1). Evidence for coronary artery disease, with hypertension as a major risk factor, 






was not associated with critically stenosing or thrombosed coronary lesions. The other patient 
displayed a fibrotic scar consistent with an old myocardial infarction without signs of recent-
onset ischemia. 
 
Decreased pacemaker treatment efficacy in SCN5A-1795insD mutation-positive patients older 
than 40 
Mutation-positive patients died suddenly predominantly during the night, and excessive QT-
prolongation during (nocturnal) bradycardic episodes was frequently documented on Holter 
recordings.
3,4,7
 Hence, a bradycardia-dependent trigger for arrhythmia was originally suspected, 
and pacemaker implantation has been routinely employed in the family to prevent SCD.
4
 While 
this approach initially proved successful,
4
 in the last decade 7 mutation-positive individuals 
suffered ventricular tachyarrhythmias and/or SCD despite pacemaker implantation (Figure 1A). 
All of them were older than 40 (age range 41-58 years), and in the majority, ventricular 
fibrillation or tachycardia was documented (Table 1), in addition to ventricular extrasystoles 
recorded during Holter monitoring or exercise testing in several cases. Figure 1D shows a 
pacemaker readout showing a nocturnal, fast ventricular tachycardia (presumably polymorphic) 
in a 58-year old female mutation-positive patient; following this episode, her pacemaker was 
replaced with an ICD. These observations suggested an age-dependent shift towards a different 
arrhythmia triggering mechanism at older age with arrhythmias occurring despite prevention of 
bradycardia. Indeed, comparing the occurrence of SCD/life-threatening arrhythmia between 
individuals with and without pacemaker showed that while pacemaker implantation was highly 
protective in young mutation-positive patients, its efficacy in preventing arrhythmias and SCD 






of pacemaker implantation tested using the Schoenfeld residuals from a Cox regression model) 
(Figure 1C). Importantly, in 6 of the 7 mutation-positive patients who suffered a life-threatening 
event despite pacemaker treatment, a history of hypertension was confirmed and/or the presence 
of left ventricular hypertrophy documented on MRI, echocardiography, or post-mortem 
examination (Table 1). These observations led us to hypothesize that the co-occurrence of the 
mutation with cardiac hypertrophy, developing with age secondary to for instance hypertension, 
plays a pivotal role in modulating arrhythmia risk. 
 
The co-occurrence of cardiac hypertrophy is pro-arrhythmic in aged Scn5a
1798insD/+
 mice  
We further explored the modulatory role of cardiac hypertrophy in Scn5a
1798insD/+
 mice carrying 
the exact mouse homolog of the human SCN5A-1795insD mutation.
5,8
 We have previously 
generated two distinct mouse lines harbouring the Scn5a
1798insD/+
 mutation, with respectively the 
FVB/N and 129P2 inbred genetic background, enabling investigation of the effect of the 
mutation on different genetic backgrounds. In young adult mice we previously demonstrated 
strain-dependent variable disease severity, with more pronounced conduction slowing and 
prolongation of repolarization in mutant mice of the 129P2 strain.
8
 We now studied aged wild-
type (WT) and Scn5a
1798insD/+
 mutant (MUT) mice of both strains. The 129P2 strain was found to 
develop more cardiac hypertrophy with age as compared to the FVB/N strain. This feature was 
intrinsic to the 129P2 strain and independent of the mutation, since both aged WT- and MUT-
129P2 mice displayed greater heart weight and higher expression levels of pro-hypertrophic 
markers as compared to aged WT- and MUT-FVB/N mice (Figure 2A,B). These intrinsic strain-
dependent differences in susceptibility to hypertrophy enabled a comparison of the pro-






aged FVB/N-MUT mice) of hypertrophy. We therefore conducted ECG studies in anesthetized 
mice and electrophysiological studies in Langendorff-perfused hearts, comparing aged (8-22 
months old) WT and MUT mice of both strains. This indeed uncovered a genotype-strain 
interaction, where aged 129P2-MUT mice displayed significantly more pronounced ventricular 
conduction slowing in vivo (QRS-duration on ECG analysis; Figure 2C,D; Supplementary Table 
1) and ex vivo (LV activation time in isolated Langendorff-perfused hearts; Figure 2F,G). 
Moreover, 129P2-MUT mice exhibited significantly more spontaneous ventricular extrasystoles 
and arrhythmias in vivo (Figure 2C,E) and an increased inducibility of ventricular arrhythmias ex 
vivo (Figure 2H,I). While these observations do not provide a causal link, they are in line with a 
pro-arrhythmic interaction between hypertrophy and the mutation, similar to our observations in 
the SCN5A-1795insD family.  
 
Chronic pressure overload elicits conduction delay and sudden death in Scn5a
1798insD/+
 mice 
To provide direct evidence for a modulatory effect of hypertrophy in the setting of the mutation, 
we subjected adult FVB/N-WT and FVB/N-MUT mice (10-12 weeks old) to transverse aortic 
constriction (TAC; duration of 2 weeks), an intervention which leads to chronic pressure 
overload and consequent development of cardiac hypertrophy. TAC induced similar extent of 
hypertrophy in WT and MUT mice, as illustrated by equal increases in heart mass and 
upregulation of hypertrophic genes (Figure 3B,C; Supplementary Table 2). However, 
approximately 35% of MUT-TAC mice died suddenly during the 2-week post-TAC period, 
while all WT-TAC and sham mice survived (Figure 3A). Continuous 24-hour telemetric ECG 
recordings in a subset of MUT-TAC mice revealed progressive bradycardia and excessive (atrio-






surviving MUT mice post-TAC uncovered a more pronounced increase in QRS-duration 
compared to WT (Supplementary Table 3). Moreover, ex vivo measurements in isolated 
Langendorff-perfused hearts post-TAC showed atrio-ventricular delay and exacerbated 
ventricular conduction slowing in MUT but not WT mice (Figure 3D-G; Supplementary Table 
2). Hence, TAC elicited SCD and conduction abnormalities in MUT mice only, indicating a 
synergistic, deleterious interaction between cardiac hypertrophy and the mutation. 
 
TAC-induced conduction abnormalities and SCD in Scn5a
1798insD/+
 mice are attenuated by 
decreasing the hypertrophic response through genetic inhibition of the calcineurin-Nfat pathway  
Activation of the calcineurin-Nfat (Nuclear Factor of Activated T-cells) signaling pathway is 
known to play a major role in mediating the pro-hypertrophic consequences of chronic pressure 
overload of the heart. To investigate whether the more severe electrophysiological abnormalities 
in FVB/N-MUT mice post-TAC are the direct consequences of cardiac hypertrophy and not to 
other (indirect) effects of pressure overload, we abrogated the hypertrophic response by inducing 
genetic deletion of the main downstream effector of the calcineurin-Nfat pathway by crossing 
Scn5a
1798insD/+




 WT and MUT (Scn5a
1798insD/+
) mice 
deficient for Nfatc2 (Nfatc2
-/-
), and littermate WT and MUT animals with unaltered Nfatc2 
expression (Nfatc2
+/+
), were subjected to TAC for a period of 2 weeks. As expected, cardiac 





), as illustrated by lower heart weights and lower 





4B,C, Supplementary Table 4). No SCD was observed in MUT-Nfatc2
-/- 
mice subjected to TAC 






MUT mice with intact Nfatc2 expression were rescued in MUT-Nfatc2
-/-
 mice (Figure 4D-F; 
Supplementary Table 4). Hence, blocking the downstream, pro-hypertrophic signaling cascade 
prevented the TAC-induced conduction abnormalities and SCD in MUT mice, providing support 
for a direct interaction between the mutation and cardiac hypertrophy. 
 




We have previously demonstrated that the SCN5A-1795insD mutation is associated with multiple 
biophysical defects including a gain of channel function due to sustained (late) inward sodium 
current.
5,6
 This mutation-induced enhanced late sodium current (INa,late) can be blocked through 
pharmacological inhibition. We therefore explored whether blocking this biophysical defect of 
the mutation would prevent the exacerbation of electrophysiological abnormalities associated 
with TAC in MUT mice. For this we administered the INa,late inhibitor Ranolazine by feeding WT 
and MUT mice either control or Ranolazine chow for the 2-week period of TAC or sham 
(starting 2 days after the TAC or sham procedure). Food intake and body weights were constant 
throughout the duration of the experiment and did not differ between groups (Supplementary 
Figure 1). INa,late inhibition decreased QTc-duration in sham mice, and moreover prevented TAC-
induced QTc-prolongation (Supplementary Table 3). Blocking INa,late did not affect the 
magnitude of TAC-induced cardiac hypertrophy, as indicated by a similar increase in pro-
hypertrophic markers in WT-TAC and MUT-TAC mice that were fed Ranolazine chow (Figure 
4B,C; Supplementary Table 2). Yet, INa,late blockade prevented SCD and attenuated (atrio-
Supplementary Table 2). Hence, pharmacological inhibition of the mutation-induced enhanced 

















Our findings point to a modulatory effect of hypertension and consequent cardiac hypertrophy on 
age-dependent risk for sudden arrhythmic death and pacemaker treatment efficacy in the SCN5A-
1795insD mutation-positive patients. This is supported by our observations in Scn5a
1798insD/+
 
mice carrying the homologous mutation, where cardiac hypertrophy (either occurring with age or 
induced by TAC) led to severe conduction disturbances and an increased risk for ventricular 
arrhythmias and/or SCD. This study for the first time provides evidence for a modulatory role of 
co-morbidity in modulating disease severity of an inherited arrhythmic disease, demonstrating a 
pro-arrhythmic gene-environment interaction.  
 
Modulatory effect of cardiac hypertrophy on (age-dependent) arrhythmic phenotype  
Cardiac hypertrophy, which commonly occurs as a consequence of hypertension, develops over 
time and progressively remodels the myocardium. Its impact is therefore expected to increase 
with age, potentially altering disease severity in mutation-positive patients in an age-dependent 
manner. The observed age-dependent shift from bradycardia-induced (prevented by pacemaker 
therapy) to apparent bradycardia-independent arrhythmias and SCD in older SCN5A-1795insD 
mutation-positive patients moreover indicates a modulatory effect on disease expression. Our 
clinical findings are further supported by our observations in Scn5a
1798insD/+
 mice, where mice 
from the strain most prone to age-dependent hypertrophy (i.e. 129P2-Scn5a
1798insD/+
 mice) 
developed a more pronounced arrhythmic phenotype with significantly more spontaneous and 
inducible ventricular arrhythmias. Although other factors besides hypertrophy, that differ 






human and mouse data support the concept that age-dependent development of cardiac 
hypertrophy interacts with sodium channel dysfunction to predispose the heart to ventricular 
arrhythmias and SCD. Data obtained in the TAC studies in young-adult Scn5a
1798insD/+
 mice 
provide direct proof of the modulatory role of hypertrophy on disease expression. Despite the 
fact that wild type and Scn5a
1798insD/+
 mice developed similar extent of cardiac hypertrophy 
secondary to TAC, SCD and conduction abnormalities were observed only in Scn5a
1798insD/+
 
mice with chronic pressure overload. In contrast to aged 129P2-Scn5a
1798insD/+
 mice however, no 
spontaneous or inducible ventricular arrhythmias were observed in mutant mice following TAC 
(data not shown). The young-adult age of the mice subjected to TAC, the relatively abrupt 
development of hypertrophy secondary to TAC (in contrast to gradual progression with age), and 
the short duration of TAC (two weeks) may underlie this apparent discrepancy. One should note 
however that as for aged Scn5a
1798insD/+
 mice, young-adult Scn5a
1798insD/+
 mice developed 
ventricular conduction slowing post-TAC, a phenomenon that is well established to promote 
ventricular arrhythmias.  
 
Potential mechanisms underlying modulatory role of hypertrophy 
The mechanisms underlying the modulatory, pro-arrhythmic effects of hypertension and 
consequent hypertrophy may be numerous and complex. Hypertrophy is associated with 
progressive electrical (alterations in sodium current and other ion channels), homeostatic 
(dysregulation of intracellular calcium homeostasis) and structural (collagen deposition) 
remodelling.
11–14
 These alterations may be further exacerbated in the setting of an SCN5A 
mutation, acting synergistically with the biophysical defects caused by the SCN5A mutation in 
creating a highly arrhythmogenic environment.
15,16






levels of hypertrophy induced a pro-arrhythmic phenotype in Scn5a
1798insD/+
 but not wild type 
mice, indicating a synergistic interaction between hypertrophy and the mutation. Moreover, 
TAC-induced conduction disturbances and SCD were prevented by either blocking the 
downstream pro-hypertrophic response (by genetic deletion of Nfatc2) or by pharmacological 
inhibition of the detrimental consequences of the mutation (i.e. through INa,late inhibition). 
Enhanced INa,late increases sodium influx, which may secondarily lead to increased intracellular 
calcium concentrations. The latter is a well-established pro-arrhythmic feature of hypertrophy 
and heart failure, and may be exacerbated in SCN5A-1795insD mutation-positive patients in the 
presence of hypertrophy.
17,18
 The involvement of the enhanced INa,late defect in mediating, at least 
in part, the observed interaction with hypertrophy is supported by the fact that targeting this 
molecular defect by INa,late blockade prevented SCD and attenuated (atrio-)ventricular conduction 
abnormalities in mutant mice post-TAC. While enhanced INa,late is a well-established pro-
arrhythmic consequence of hypertrophy,
18
 one might speculate that other hypertension-
associated pathways (including the renin angiotensin aldosterone system) may also be involved 
in mediating the role of hypertrophy in increasing arrhythmic propensity, with potential 
relevance for patient management.  
 
Implications for age-dependent treatment efficacy 
The observed age-dependent change in arrhythmia phenotype had crucial consequences for 
treatment efficacy in SCN5A-1795insD mutation-positive patients: while pacemaker implantation 
remained 100% efficacious in preventing SCD in young mutation-positive individuals, it no 
longer afforded complete protection over the age of 40. These findings therefore underline the 






combined observations in the family and in mice implicate a role for hypertension and 
consequent hypertrophy in disease expressivity with consequences for treatment efficacy, 
although other co-morbidities may also play an as yet unidentified modulatory role. Our findings 
indicate a pro-arrhythmic interaction between hypertrophy and the mutation, and prevention of 
either hypertrophy (by genetic deletion of Nfatc2) or the effect of the mutation (by Ranolazine) 
was sufficient to prevent SCD in mutant mice subjected to TAC. Hence, clinical management of 
affected patients with either INa,late inhibition or anti-hypertensive treatment (aimed at preventing 
LVH) is potentially beneficial, since either of these approaches would prevent the deleterious 
interaction between cardiac hypertrophy and the mutation. While INa,late inhibition may have 
additional (long-term) benefits aside from restoration of repolarization, including the prevention 
of intracellular sodium/calcium dysregulation, it is as yet unclear whether this therapeutic 
approach will be clinically applicable in the near future. Ranolazine may have pro-arrhythmic 
side-effects due to its (limited) IKr blocking properties, and the development of more selective 
INa,late inhibitors (including Eleclazine) was discontinued.
19,20
 Thus, while awaiting (further) 
development of novel compounds targeting INa,late,
20
 current clinical management should focus 
on carefully monitoring SCN5A-1795insD mutation-positive patients for co-morbidities such as 
hypertension. In addition, hypertension should be aggressively treated early on to prevent LVH 
development, which should be regularly monitored by echocardiography. In particular, drugs 
targeting the renin-angiotensin system may be beneficial.
21
 This approach is in line with the 2015 
ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention 
of sudden cardiac death,[REF] which state that appropriate therapy should also take into account 
underlying diseases, co-morbidities, and associated medical conditions that may contribute to 









While the homogeneity in genetic cause in the extended SCN5A-1795insD family allowed for 
detection of this interaction, it is associated with the limitation that transferability of these 
observations to other SCN5A mutations, although considered likely, will need to be explored. It 
is possible that our current findings are specific for “overlap syndrome” mutations associated 
with both a loss and a gain of sodium channel function. Furthermore, while hypertension and/or 
hypertrophy was observed in the majority of older SCN5A-1795insD mutation-positive patients 
who suffered a life-threatening event despite pacemaker treatment, we currently do not know the 











Our findings show that a common co-morbidity (e.g. hypertension) may significantly affect 
arrhythmia risk and survival in inherited sodium channelopathy. The impact of such unrelated 
co-morbidities varies with age, leading to potential age-dependent changes in arrhythmia 
mechanism. As a consequence, efficacy of treatment strategies to prevent SCD in the setting of 
inherited arrhythmic disease may vary over time, underscoring the need for continuous diagnosis 
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Figure 1. Life-threatening cardiac events in SCN5A-1795insD mutation-positive patients. 
(A) The SCN5A-1795insD founder population pedigree. Circles indicate SCN5A-1795insD 
mutation-positive patients suffering sudden cardiac death (SCD), ventricular fibrillation (VF), 
and/or ventricular tachycardia (VT) in the presence or absence of pacemaker (PM) treatment and 
hypertension and/or left ventricular hypertrophy (HYP). (B) Survival from SCD and/or 
ventricular arrhythmias was significantly reduced in SCN5A-1795insD mutation-positive patients 
(n=164) versus mutation-negative relatives (n=247) (p=1.3026E-18). (C) Overall survival from 
SCD and/or ventricular arrhythmias in SCN5A-1795insD mutation-positive patients was 
significantly higher in those with (n=87) as compared to without (n=77) pacemaker 
(p=0.000003), but pacemaker efficacy was significantly reduced in mutation-positive patients 
above the age of 40 years (p=0.028; Cox regression model). (D) Pacemaker readout (A:atrial 
lead; V:ventricular lead; paper speed 25 mm/sec) of a 58-year female mutation-positive patient 
showing a nocturnal, fast (up to 300/min) and apparently polymorphic VT despite adequate anti-
bradycardia treatment.  
 
Figure 2. Pro-arrhythmic effects of cardiac hypertrophy in aged Scn5a
1798insD/+
 mice. Mice 
of the 129P2 strain develop more severe cardiac hypertrophy with age (WT, wild type and MUT, 
Scn5a
1798insD/+
 to a similar extent) than mice of the FVB/N strain, as indicated by increased heart 
weight to body weight ratio (A) and Anf expression on in situ hybridization (B). (C) Typical 
examples of surface ECGs and arrhythmias. (D,E) Aged 129P2-MUT mice show significantly 






p=0.000039) on ECG than aged 129P2-WT, FVB/N-WT and FVB/N-MUT mice (SND: sinus 
node dysfunction; AVB: atrio-ventricular block; VPBs: ventricular premature beats; VT: 
ventricular tachycardia). (F) Typical examples of left ventricular (LV) activation maps 
(stimulation at 120 ms) obtained by optical mapping. (G) Aged 129P2-MUT mice display 
significantly longer LV activation times, indicating more pronounced conduction slowing. (H) 
Typical example of a VT induced by 1 short-coupled extra stimulus (S1) in an isolated aged 
129P2-MUT heart, and non-inducibility in an aged FVB/N-MUT heart with up to 3 extra stimuli 
(S1-S3). (I) Isolated aged 129P2-MUT hearts display significantly higher inducibility of 
ventricular arrhythmias (Pearson Chi-square overall p=0.03). Panel D: median(IQR); all other: 
mean±SD. 
 
Figure 3. Cardiac hypertrophy induced by transaortic constriction (TAC) causes SCD and 
conduction disturbances in Scn5a
1798insD/+
 mice. (A) Kaplan-Meier survival curves of WT and 
MUT mice subjected to Sham or TAC. (B,C) Magnitude of cardiac hypertrophy (measured by 
heart weight/tibia length ratio (B) and mRNA expression levels of the pro-hypertrophic marker 
Rcan1-4 (C)) secondary to TAC is similar in WT and MUT mice. (D) Typical examples of atrio-
ventricular (AV) delay measurements (atrial stimulation, 120 ms). (E) MUT-TAC mice display 
more severe AV-conduction delay versus WT-TAC. (F) Typical examples of LV activation 
maps (stimulation at 120 ms). (G) MUT-TAC mice display increased LV activation time. Panel 
G: median(IQR); all other: mean±SD. Additional data is presented in Supplementary Table 2. 
 
Figure 4. Rescue of TAC-induced SCD and conduction disturbances in Scn5a
1798insD/+
 mice 






Meier survival curves of WT and MUT mice (Nfatc2
-/-
: with genetic deletion of Nfatc2; RAN: 
fed Ranolazine chow) subjected to Sham or TAC. (B,C) Magnitude of cardiac hypertrophy 
(measured by heart weight/tibia length ratio (B) and mRNA expression levels of Rcan1-4 (C)) 
secondary to TAC is similar in WT and MUT (+/- Ranolazine chow) mice, but lower in WT and 
MUT mice on a Nfatc2
-/-
 background. (D) Typical examples of atrio-ventricular (AV) delay 
measurements (atrial stimulation at 120 ms). The AV-conduction delay induced by TAC in MUT 
mice is reversed by genetic inhibition of Nfatc2 and by Ranolazine. (E) Typical examples of LV 
activation maps in isolated hearts. (F) Increased LV activation time induced by TAC in MUT 
mice is reversed by genetic inhibition of Nfatc2 and by Ranolazine. In panels B,C,D and F, data 
is presented as ratio for TAC versus Sham (mean±SD); actual values are in Supplementary 
Tables 2 and 4. 
  
Table 1. Characteristics of SCN5A-1795insD mutation-positive patients suffering a serious cardiac event above the age of 40 
with available recent clinical information 
Gender Age  PM Event Hypertension Hypertension-related cardiac findings Comments/other findings 
Male 45 Yes SCD Yes 
Postmortem: HW 490 gr, concentric 
LVH, slight interstitial myocardial 
fibrosis  
SCD (VF documented) 
Postmortem: <50% stenosing coronary atherosclerosis; 
small foci of subendocardial necrosis; no valvar stenosis 
Female 55 Yes SCD Borderline MRI: LVH SCD at night; previously documented VT 
Female 46 Yes SCD Yes 
Postmortem: HW 550 gr, concentric LVH,  
interstitial fibrosis 
SCD at night 
Postmortem: minimal coronary atherosclerosis; no valvar 
stenosis 
Female 49 Yes SCD Yes 
Postmortem: HW 470 gr, concentric 
LVH, slight interstitial fibrosis 
SCD at night 
Postmortem: minimal coronary atherosclerosis; no valvar 
stenosis  
Female 41 Yes VF No* Echo: marginal LVH VF (resuscitated successfully) 
Female 50 Yes SCD Yes Echo: possible DCM  SCD (VF documented)  
Female 58 Yes VT Yes Echo: diastolic dysfunction VT documented at night necessitating ICD implantation 
Female 69 No VT/VF Yes Unknown 
Multiple episodes of syncope; documented  
polymorphic VTs 
Male 60 No SCD Yes Unknown  Normal echo 1 year prior to SCD 
Male 69 No SCD Yes Postmortem: HW 530 gr, concentric LVH 
SCD (VF documented) 
Postmortem: ischemic scar; no signs of recent-onset 
ischemia; no valvar stenosis 
PM: pacemaker; DCM: dilated cardiomyopathy; ICD: implantable cardioverter defibrillator; LVH: left ventricular hypertrophy; SCD: sudden cardiac death; 
VF: ventricular fibrillation; VT: ventricular tachycardia 
*Patient did not have documented hypertension prior to VF, but developed clinically relevant hypertension one year later   
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